CDK2 and breast cancer: For instance, breast cancer patients almost invariably develop resistance to CDK inhibitors through diverse molecular mechanisms, including loss of RB1, upregulation of Cyclin E/CDK2 by CCNE1 amplification or c-MYC overexpression, amplification of AURKA, or loss of FAT1 (23–27).